Background and Purpose-Statin use may be associated with improved outcome in intracerebral hemorrhage patients.
I
ntracerebral hemorrhage (ICH), the second most common subtype of stroke, comprises 10% to 15% of all stroke cases. 1 It is a devastating disease, with 30-day mortality over 40%. 2 Despite extensive research and allocation of resources, treatment options are limited, typically involving supportive care and control of hypertension. Many neuroprotective agents have failed to find a proven benefit. 3 Hypocholesterolemia has been associated with increased incidence of ICH, and it has also been associated with hematoma expansion after ICH. [4] [5] [6] [7] [8] [9] [10] Hydroxymethylglutaryl-CoA reductase inhibitors (statins) are the class of medications most often used for lowering cholesterol. Current cholesterol management guidelines favor aggressive statin therapy in patients with cardiovascular risk factors. 11 The impact of these guidelines may result in the aggressive use of high-dose statins in the elderly population in coming years, although there may be a modest risk of increased incidence of hemorrhagic strokes after statin use. 12, 13 The role of statins as a neuroprotective agent has become an area of increasing interest, especially in the setting of a disease with limited treatment options, such as ICH. Animal models have supported the use of statins in patients with ICH. [14] [15] [16] [17] [18] The potential beneficial pleiotropic effects of statins include endothelial stabilization, antithrombotic properties, anti-inflammatory actions, and upregulation of endothelial nitric oxide synthase. 19 However, there have been conflicting results regarding ICH outcomes after statin use (Table I in the online-only Data Supplement). Limitations of prior studies include small sample sizes, single-center data, retrospective design, and lack of post-discharge outcomes. Some studies lack a clear definition of statin use or they do not account for statin discontinuation. Some rely on unadjusted analyses or multivariate models that are not adjusted for confounding factors, such as the inability to swallow statins, withdrawal of care, or the treating physician's view of patient's long-term prognosis.
Jung et al 20 performed a recent meta-analysis of 16 studies that examined the effect of statin use and ICH outcomes. Prior statin use was associated with decreased risk of mortality at 3 months after symptom onset, as well as an increased probability of good functional outcomes, compared with those who were not on statins before ICH. The authors acknowledged several limitations, including substantial study-to-study design variations, leading to unresolved heterogeneity, and inability to adjust variables determining ICH outcomes, such as initial injury severity, withdrawal of care, lipid parameters, volume and location of hematoma, and use of antithrombotic medications. 20 The ERICH study (Ethnic/Racial Variations of Intracerebral Hemorrhage) was a multicenter, prospective recruitment, multiethnic study of ICH. 21 Using the ERICH data set, we explored the association of statin use with ICH outcomes, including ICH mortality and 3-month disability, as well as initial hematoma volume and subsequent expansion. Given the association of hypocholesterolemia with increased risk of ICH, we hypothesized that ICH patients who were on statins would have larger admission hematoma volume, increased risk of hematoma expansion, and higher 3-month mortality and morbidity.
Materials and Methods

Data Source
ERICH was a multicenter prospective study, with a goal of identifying differences in risk factor distribution, neuroimaging parameters, and outcomes of ICH by race/ethnicity. Cases were identified by hot pursuit and enrolled using standard phenotype and risk factor information. Each case underwent neuroimaging and provided a blood sample.
Patient Population
For the current analysis, we included ICH patients whose 3-month vital status was known and who had data on initial hematoma volume. Functional outcome at 3 months was assessed using modified Rankin Scale (mRS). Baseline data included statin use, age, sex, race/ ethnicity (non-Hispanic white, non-Hispanic black, or Hispanic), prior history of ischemic stroke, apolipoprotein E genotype, coronary artery disease, diabetes mellitus, dementia or Alzheimer's disease, hypertension, hypercholesterolemia, use of antiplatelet or anticoagulants within 2 weeks prior to onset, and use of alcohol during the 3 months prior to onset. Statin use was further trichotomized into prior-only use, prior and continued use, and new use. Non-statin users were those patients who were not on any statins prior or after ICH. The ICH location was categorized into lobar, deep (including primary intraventricular hemorrhage), brain stem, and cerebellum. Data collected in the acute setting included Glasgow Coma Scale (GCS) in the emergency department, time from onset to arrival in the emergency department, hematoma volume on each computed tomographic (CT) imaging, presence and location of microbleeds, and low-density lipoprotein on admission. Change in hematoma volumes was measured between the initial CT scan (within 6 hours of onset) and the followup CT scan (6 hours to 5 days later).
Representativeness of the ERICH Population
Prior studies had identified the potential for a survival and mild severity bias in the recruitment of cases, which led to modifications in recruitment procedures instituted for the current study. 22 Hot pursuit recruitment, rather than retrospective recruitment, uses the same methods of acute ICH case identification used for clinical trials, including active screening of admission logs and emergency room, neurosurgical intensive care unit, neurosurgery, and neurology records. In addition, given that the most severe cases are the least likely to participate, our personnel have received in-person and onsite training on effective ways to approach patients and families for enrollment. Finally, almost all cases had a clinically drawn sample that was available for genetic testing. Families with a moribund case, unable to come to a decision to enroll in the immediate hyperacute setting, were asked if the clinically drawn sample could be held and not discarded so that they could have more time to consider the study, allowing us to reapproach later. This innovation reduced recruitment bias that otherwise would have accrued with pre-enrollment attrition of the most severe cases because of early death and inability at time of delayed family consent to obtain the research sample. In no case did the study take possession of the clinically drawn sample until full and finalized consent was formally obtained. (This process was approved by the Institutional Review Boards at participating sites.)
We evaluated the representativeness of our population by performing chart abstractions of true cases of ICH who were not enrolled in the study over a 6-month period within the case recruitment period (Table II in the online-only Data Supplement). Enrolled patients were slightly younger (62 versus 65 years; P<0.0001) but were not different in risk factor comparison for anticoagulant use, frequent alcohol use, hypertension, diabetes mellitus, or hypercholesterolemia. Further, discharge disposition to home/relative versus rehabilitation, skilled nursing facility/assisted living, or other hospital/subacute setting was not different between enrolled versus nonenrolled (P=0.18). There was a higher mortality in the not enrolled patients versus enrolled patients (32% versus 11%; P<0.0001) within the 6-month case recruitment period. This creates a potential for survival bias. The study did show that Hispanics were more likely to enroll than nonHispanic ICH cases.
Primary and Secondary Outcomes
The primary outcomes of interest were the effect of statin use on 3-month mortality and mRS in ICH patients. Secondary outcome of interest was the effect of statins on hematoma growth in patients whose first CT scan was within 6 hours of onset and had an available follow-up CT scan.
Statistical Analysis
All statistical analyses were 2-tailed and considered significant if P≤0.05. We compared patient characteristics, clinical data, and hospital characteristics in ICH patients between statin users (total, prior, new, or continued) and nonstatin users. To compare patients' characteristics and outcomes of interest between statin and nonstatin users, categorical variables were presented as counts and proportions, and differences between groups were tested using chi-squared or Fisher exact test for R×C tables. Means, standard deviations, and medians for continuous variables were reported. Comparisons of hematoma volumes, lipid laboratory values, age, and admission GCS were made using the Kruskal-Wallis test. Comparison of alcohol use, location of ICH, differences in hematoma volumes, and time from onset to arrival at emergency department were made using the CochranMantel-Haenszel test. In multivariate modeling, logistic regression 
Results
Two thousand nine hundred and ninety-seven cases of ICH were recruited in the study. Of the 2997 cases enrolled, 431 cases were excluded because of lack of 3-month mRS. An additional 74 were excluded because of missing data on hematoma volume, and another 35 were excluded because of unreliable data on time of onset to first CT or arrival. Our final study population was 2457 patients (1093 statin users, and 1364 nonstatin users). In the statin user group, 268 (25%) patients were prior users, 402 (37%) were newly prescribed, and 423 (39%) were continued on statins after the admission. Among the final study population, CT head within 6 hours of onset was available for 849 patients (35%), with followup CT head available in 628 (26%) cases. Data on admission low-density lipoprotein was available for 1416 (58%) patients. The mean age of the study sample was 62 years, and 42% of patients were women. Tables 1 and 2 compare the baseline characteristics and outcomes of interest among statin and nonstatin users, respectively (A detailed version is included in the online-only Data Supplement (Table III in the onlineonly Data Supplement). The time from symptom onset to emergency department arrival was similar between 2 groups. Overall, statin users were older, with significantly higher rates of medical comorbidities, including hypertension, diabetes mellitus, hyperlipidemia, prior history of ischemic stroke, and prior use of antiplatelet and anticoagulant therapy. Statin use was significantly more common in white cases, compared with blacks and Hispanics (P<0.0001). A higher proportion of statin users had lobar hemorrhages compared with nonstatin users (P=0.03). There was no statistical difference in the specific apolipoprotein E genotypes between the 2 groups (P=0.27). There was no statistical difference in the average rates of microbleeds between the 2 groups (P=0.67). There was also no statistical difference in the location of microbleeds between the 2 groups ( Table 1; Table III in the online-only Data Supplement). However, when the statin user subgroups were separately analyzed, there was a statistically higher percentage of new statin use in patients with nonlobar and nonlobar plus lobar subgroups and a statistically lower use of new statins in patients with lobar only microbleeds (Table IV in 
Statin Use and Outcomes of Interest
Overall, there was a significantly higher risk of death (inhospital or postdischarge within 3 months) and disability (3-month mRS) among nonstatin users, compared with statin users. 
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We did not detect an association between statin use and either admission hematoma volume or hematoma growth ( Table 2; Table III in the online-only Data Supplement).
Several patients were sequentially removed from the multivariate analysis to address various potential biases (patients with no CT scan within 6 hours of admission, N=1608; patients who were unable to swallow a statin pill or who had care withdrawn, N=155). Despite removing these patients and after adjustment for initial volume of hemorrhage, GCS, presence of intraventricular hemorrhage, antiplatelet and anticoagulant use, sex, race, ICH location, age, and prestroke mRS, the final multivariate analysis continued to show lower mortality with statin use at 3-month follow-up (Table 3 ; P=0.04). Statin use was not significantly associated with 3-month mRS in this analysis.
When a subgroup multivariate analysis was performed to compare various statin user groups, prior-only statin users appeared to have significantly higher mortality (P=0.003) and disability (P=0.05) compared with new or continued users (Table 3) .
Propensity Score Analysis (Prior-Only Statin Users Versus New or Continued Statin Users)
The overall good outcome in all statin users but worse outcomes in prior-only statin users create a scientific dilemma. Was the higher mortality and morbidity in prior statin users a result of stopping statins on admission or that prior statin users were a group of extremely sick patients who were not prescribed statins during the hospital course or discharge because of their poor prognosis? To address this question, we developed a propensity score to match the odds of continuing statins and stopping statins based on variables (see Methods) that would influence a treating physician's decision. The set of samples with complete data, after excluding for dysphagia, withdrawal of care, and baseline CT after 6 hours of onset, was much smaller (N=60 prior use, N=267 new/continued use). Prior statin users were significantly older, had significantly lower admission GCS, and significantly higher admission hematoma volume. When this propensity score was added as a covariate in the initial model of prior statin users versus new or continued statin users, the effect of prior statin use was dampened and no longer statistically associated with higher mortality (P=0.17). Age, admission injury severity, and hematoma volume influenced a treating physician's decision of whether to start or continue statins during admission or discharge (Table 4 ).
Discussion
The findings of our study shed light on the conflicting data regarding the effect of statins on outcomes after ICH. ICH is a complex disease and involves several factors that independently or codependently affect the outcome of these patients. In our population, statin use was associated with better outcomes in ICH patients, but this effect was driven by patients in whom statins were continued in the hospital. Prior statin users who had their statins stopped had higher 3-month mortality and morbidity that persisted even after controlling for patients †Following variables were used in the multivariate analysis: admission hematoma volume (within 6 h of onset), age, sex, race, intraventricular hemorrhage, location, Glasgow Coma Scale, prestroke modified Rankin Scale, and use of antiplatelet or anticoagulants. with withdrawal of care or dysphagia, limiting the ability to swallow. A superficial analysis may suggest that continued or new use of statins may, thus, be associated with better outcome in statin users. However, by using propensity score analysis, we found that factors influencing a treating physician's decision to continue or prescribe new statins were the most likely explanation. Thus, our analysis supports the hypothesis that prescription of statins (whether continued or new) reflected the physician/healthcare team's view of whether the person would survive. Statins were stopped in patients who were older, had lower admission GCS scores, or had larger admission hematoma volume, likely prompting a treating physician to consider these patients a poor candidate for a long-term prevention therapy like statins, even if the withdrawal of care was not invoked. The propensity score analysis based on the likelihood of having statins continued showed that after controlling for this factor, the mortality for stopping statins was no different than for continuing. This careful interpretation of the study also explains the findings of prior similar studies that showed improved survival in patients on continued inpatient statins, despite matching the groups and controlling for withdrawal of care and dysphagia. 23 There are several other noteworthy findings from our study. Our study failed to show any difference in admission hematoma volumes (when first CT scan was done within 6 hours of the time of onset) and hematoma growth (when the follow-up scan was available within 5 days of onset). Prior studies had suggested that statin use may have beneficial effects based on reducing hematoma volume or preventing growth, but our data do not confirm such an effect. Statin users were overall an older, less healthy population with multiple medical comorbidities who were on several other medications that could affect ICH volume, growth, and overall prognosis of a patient. There was an overall higher use of new statin in patients with nonlobar and nonlobar plus lobar microbleeds and lower use of new statins in patients with lobar only microbleeds. The higher percentage use of new statins preferentially in the presence of nonlobar microbleeds could be related to several associated vascular risk factors that warrants use of statins in such patients. The lower percentage use of new statins in lobar only microbleed patients could be a reflection of the known association of statin use and recurrent ICH in patients with lobar microbleeds. 24 Overall, our study has several strengths. Our study accounts for many of the limitations noted by Jung et al. 20 Our cohort is large, and the data were collected prospectively from multiple sites across the country. Ample power allowed us to control for multiple potential confounding factors. We initially controlled for traditional factors influencing outcomes in ICH patients followed by removing patients with withdrawal of care and dysphagia from the initial sample and reanalyzing the data. We later developed a propensity score and used it as a covariate to control for factors that may influence a physician's decision making.
Our study has a few limitations. This study was not designed as a randomized trial of statin therapy on ICH patients. We did not study the effect of statin types or strength of dosing. A large percentage of patients did not have admission lipid panels, which limited an analysis based on low-density lipoprotein values and statin use. However, there are numerous studies pointing toward the relationship of low low-density lipoprotein and ICH risk and outcomes that are beyond the scope of this discussion. Additionally, propensity scores were computed based on a small subset of statin users because of missing data for some variables used in calculating the propensity score.
Conclusion
Although statin use, especially continued or new use of statins, was associated with improved outcomes in ICH patients, this effect may merely reflect the physician/healthcare team's view of whether the person will survive and not a predictor of survival. We were unable to identify a substantial effect of statin use on long-term survival, outcomes, and hematoma volume or hematoma growth.
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